Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 5/20 | 0.41 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.41 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12544570 | 0.91 | ERN1 (0.44) | ERN1PRKD1NPSR1PHGDHGRM5 | |
| SCHEMBL2029037 | 0.88 | TDP2 (0.45) | TDP2ADCY8ADCY1GRM5KAT6A | |
| SCHEMBL12543892 | 0.86 | GABRG2 (0.49) | ERN1TDP2GRM5 | |
| SCHEMBL10475895 | 0.85 | FYN (0.54) | TDP2GRM5 | |
| SCHEMBL2031842 | 0.84 | KMO (0.44) | TDP2GRM5 | |
| SCHEMBL2034264 | 0.82 | CNR1 (0.45) | ERN1TDP2 | |
| SCHEMBL2032459 | 0.82 | FYN (0.46) | ERN1TDP2 | |
| SCHEMBL2009206 | 0.81 | GRM5 (0.46) | TDP2GRM5KAT6A | |
| SCHEMBL12544761 | 0.80 | MAPK1 (0.49) | ERN1 | |
| SCHEMBL2034297 | 0.80 | KDM5A (0.44) | TDP2GRM5KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507238-B1 | DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT | SANOFI SA (FR) | 2013-07-31 | — | — | EP | claimed |
| EP-2507238-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-10-10 | — | — | EP | claimed |
| WO-2011067544-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | WO | claimed |
| US-8680096-B2 | Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators | SANOFI-AVENTIS (FR) | 2014-03-25 | — | — | US | disclosed |
| EP-2507238-B1 | DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| EP-2507238-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011067544-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | NR4A3, NCOR1, NR4A2 | ERN1 1946/4885TDP2 2587/4885PRKD1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.